Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

09 avr. 2014 08h00 HE | Source: Aegerion Pharmaceuticals, Inc.

Aegerion Pharmaceuticals Initiates Phase 3 Clinical Trial in Japan to Evaluate Lomitapide for Treatment of Homozygous Familial Hypercholesterolemia (HoFH)

CAMBRIDGE, Mass., April 9, 2014 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of novel therapies for...
20 janv. 2014 08h00 HE | Source: Aegerion Pharmaceuticals, Inc.

Aegerion Pharmaceuticals' JUXTAPID(R) (lomitapide) Capsules Approved in Mexico for the Treatment of Homozygous Familial Hypercholesterolemia (HoFH)

CAMBRIDGE, Mass., Jan. 20, 2014 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies...
18 nov. 2013 16h00 HE | Source: Aegerion Pharmaceuticals, Inc.

Aegerion Pharmaceuticals Presents Data From Phase 3 Extension Study of JUXTAPID(TM) (lomitapide) Capsules in Homozygous Familial Hypercholesterolemia (HoFH) at AHA Scientific Sessions

CAMBRIDGE, Mass., Nov. 18, 2013 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of novel, life-altering...
05 mars 2012 07h00 HE | Source: Aegerion Pharmaceuticals, Inc.

Aegerion Pharmaceuticals Submits Marketing Applications for Lomitapide in U.S. and EU

CAMBRIDGE, Mass., March 5, 2012 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), an emerging biopharmaceutical company focused on the development and commercialization of novel...